Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL ((R-HAD))
Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Sponsor: ClinAssess GmbH
Listed as NCT01449344, this PHASE3 trial focuses on Mantle Cell Lymphoma and remains ongoing. Sponsored by ClinAssess GmbH, it has been updated 8 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Apr 2019 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Jan 2017 — Mar 2017 [monthly]
Unknown Status PHASE3
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ClinAssess GmbH
- GELARC Service de Pharmacovigilance, Pierre Benite
- Klinikum der Universitaet Muenchen, Grosshadern
- Prof. Dr. M. Dreyling (co-chairman)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Altötting, Germany , Amberg, Germany , Argenteuil, France , Bayonne, France , Berlin, Germany , Blois, France , Bordeaux, France , Bottrop, Germany , Burgwedel, Germany , Cologne, Germany and 40 more locations